Enliven Therapeutics, Inc.
ELVN
$21.00
$0.442.14%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.26% | 22.78% | 12.98% | 75.14% | 73.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.29% | 16.18% | 21.96% | 25.51% | 17.95% |
| Operating Income | 7.29% | -16.18% | -21.96% | -25.51% | -17.95% |
| Income Before Tax | 12.99% | -28.49% | -25.53% | -19.67% | -11.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.99% | -26.99% | -25.53% | -19.67% | -11.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.99% | -26.99% | -25.53% | -19.67% | -11.49% |
| EBIT | 7.29% | -16.18% | -21.96% | -25.51% | -17.95% |
| EBITDA | 7.24% | -16.22% | -22.04% | -25.60% | -18.01% |
| EPS Basic | 32.35% | -17.16% | -5.45% | 1.30% | 5.24% |
| Normalized Basic EPS | 32.58% | -13.95% | -5.44% | -9.80% | -1.42% |
| EPS Diluted | 32.35% | -17.16% | -5.45% | 1.30% | 5.24% |
| Normalized Diluted EPS | 32.58% | -13.95% | -5.44% | -9.80% | -1.42% |
| Average Basic Shares Outstanding | 28.65% | 8.38% | 19.04% | 21.23% | 17.64% |
| Average Diluted Shares Outstanding | 28.65% | 8.38% | 19.04% | 21.23% | 17.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |